PMID- 36581536
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 1879-1476 (Electronic)
IS  - 0385-8146 (Linking)
VI  - 50
IP  - 5
DP  - 2023 Oct
TI  - Omalizumab is effective for a patient with pollen-food allergy syndrome who 
      experienced intractable lip edema.
PG  - 805-810
LID - S0385-8146(22)00229-2 [pii]
LID - 10.1016/j.anl.2022.12.001 [doi]
AB  - Pollen-food allergy syndrome (PFAS) is an immunoglobulin E (IgE)-mediated 
      allergic reaction caused when patients with pollen allergy ingest food having 
      cross-reactivity with pollen. To date, no effective treatment method for this has 
      been established. Here we report the case of a patient with PFAS who experienced 
      lip edema, causing difficulties in treatment. This report describes the case of a 
      12-year-old boy with perennial allergic rhinitis since the age of 8 years. After 
      ingesting fresh fruits and raw vegetables at the age of 11 years, he started to 
      experience lip edema repeatedly. Thus, the patient was referred to our 
      department. Based on the results of serum antigen-specific IgE, prick-to-prick, 
      and allergen component tests, he was diagnosed with PFAS. He has been instructed 
      to avoid causative food. Furthermore, the treatment using an antihistamine and 
      antileukotriene receptor antagonist was initiated for pollen allergy. Sublingual 
      immunotherapy (SLIT) for Japanese cedar pollen was initiated because the patient 
      experienced severe nasal allergy symptoms during the dispersal season of this 
      pollen. These treatments alleviated the nasal symptoms; however, the lip edema 
      persisted. Omalizumab administration improved the lip edema. The combination of 
      SLIT and omalizumab may be an effective treatment option for patients with PFAS.
CI  - Copyright (c) 2022 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, 
      Inc. Published by Elsevier B.V. All rights reserved.
FAU - Sakamoto, Daiki
AU  - Sakamoto D
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan.
FAU - Hamada, Satoko
AU  - Hamada S
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan; Allergy center, Kansai Medical University, Osaka, 
      Japan. Electronic address: hamadas@kouri.kmu.ac.jp.
FAU - Kobayashi, Yoshiki
AU  - Kobayashi Y
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan; Allergy center, Kansai Medical University, Osaka, 
      Japan.
FAU - Shimono, Masami
AU  - Shimono M
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan.
FAU - Shimamura, Akihiro
AU  - Shimamura A
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan.
FAU - Kanda, Akira
AU  - Kanda A
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan; Allergy center, Kansai Medical University, Osaka, 
      Japan.
FAU - Asako, Mikiya
AU  - Asako M
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan; Allergy center, Kansai Medical University, Osaka, 
      Japan.
FAU - Iwai, Hiroshi
AU  - Iwai H
AD  - Department of Otorhinolaryngology, Head and neck surgery, Kansai Medical 
      University, Osaka, Japan.
LA  - eng
PT  - Case Reports
DEP - 20221227
PL  - Netherlands
TA  - Auris Nasus Larynx
JT  - Auris, nasus, larynx
JID - 7708170
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Fluorocarbons)
SB  - IM
MH  - Male
MH  - Humans
MH  - Child
MH  - *Rhinitis, Allergic, Seasonal/complications/drug therapy
MH  - Omalizumab/therapeutic use
MH  - Lip
MH  - Pollen
MH  - Allergens
MH  - *Food Hypersensitivity/complications/drug therapy
MH  - Syndrome
MH  - Immunoglobulin E
MH  - *Angioedema
MH  - Edema/etiology/therapy
MH  - *Fluorocarbons
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Omalizumab
OT  - Pollen-food allergy syndrome (PFAS)
OT  - Sublingual immunotherapy (SLIT)
COIS- Declaration of Competing Interest The authors have no conflicts of interest to 
      declare.
EDAT- 2022/12/30 06:00
MHDA- 2023/07/17 06:42
CRDT- 2022/12/29 21:56
PHST- 2022/06/18 00:00 [received]
PHST- 2022/11/18 00:00 [revised]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/29 21:56 [entrez]
AID - S0385-8146(22)00229-2 [pii]
AID - 10.1016/j.anl.2022.12.001 [doi]
PST - ppublish
SO  - Auris Nasus Larynx. 2023 Oct;50(5):805-810. doi: 10.1016/j.anl.2022.12.001. Epub 
      2022 Dec 27.